{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451729940
| ImageFile=Sulfadicramide.png
| ImageSize=180px
| IUPACName=N-(4-aminophenyl)sulfonyl-3-methylbut-2-enamide
| OtherNames=
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7WZ5EG263C
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=115-68-4
| PubChem=8281
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104910
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07412
| SMILES=CC(=CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N)C
  }}
|Section2={{Chembox Properties
| Formula=C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>S
| MolarMass=254.30546 g/mol
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = S01
| ATCCode_suffix = AB03
}}
|Section7={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}
'''Sulfadicramide''' (marketed as '''Irgamid''') is an anti-infective.<ref>{{Cite journal 
| last1 = Grześkowiak | first1 = E. 
| last2 = Partyka | first2 = D. 
| last3 = Simon | first3 = M. 
| last4 = Zgrabczyńska | first4 = M. 
| last5 = Wiśniewska | first5 = A. 
| title = Technology and physico-chemical evaluation of solid ocular inserts containing sulfadicramide and hyaluronic acid 
| journal = Acta poloniae pharmaceutica 
| volume = 58 
| issue = 6 
| pages = 453–458 
| year = 2001 
| pmid = 12197618
}}</ref>

==References==
{{reflist}}

{{Nucleic acid inhibitors}}

[[Category:Sulfonamide antibiotics]]
[[Category:Alkene derivatives]]


{{antiinfective-drug-stub}}